exemestane: Clinical Trials

37 trials of exemestane, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

19 completed, 6 terminated, 5 recruiting, 2 active not recruiting. 37 Phase 1, 13 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 137Completed 19, Terminated 6, Recruiting 5, Active not recruiting 2, Not yet recruiting 2, Withdrawn 2, Unknown 1
Phase 213Terminated 5, Completed 4, Recruiting 2, Not yet recruiting 1, Unknown 1

Follow exemestane: new trials by email Literature Review of exemestane trials Research Report on exemestane

Trials (filtered) newest first · largest first

All 37 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
E.N.D.E.A.V.O.R.: An Exemestane Needed Dose Efficacy and Verification as an Ovulation Induction Regimen Study
Exemestane 25 MG, Placebo, Exemestane 50 MG - Poly Cystic Ovary Syndrome
Phase 1RecruitingUniversity of North Carolina, Chapel Hill402026-10-012026-09-23
BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor Positive Breast Cancer Who Developed Hypoactive Sexual Desire Disorder
Aromatase Inhibitors, Bupropion, GnRH agonist - Early-stage Breast Cancer, Hypoactive Sexual Desire Disorder
Phase 1 / Phase 2Not yet recruitingUniversity of Illinois at Chicago1002026-09-012026-08-24
Sapu003 in Advanced mTOR-sensitive Solid Tumors
Sapu003, Exemestane 25 MG - Breast Cancer Metastatic, Renal Cell Carcinoma (RCC)
Phase 1RecruitingSAPU NANO (US) LLC272025-12-152026-01-27
A Trial to Evaluate Sacituzumab Govitecan in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Metastatic Breast Cancer Progressed on CDK4/6 Inhibitors
Sacituzumab Govitecan + Fulvestrant, Sacituzumab Govitecan + Anastrozole / Exemestane - Stage IV (Metastatic) Breast Cancer
Phase 1Not yet recruitingHunan Cancer Hospital122025-10-012025-09-16
Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ
MUC1 Peptide Vaccine, Hiltonol®, Aromatase Inhibitor - Ductal Carcinoma in Situ
Phase 1RecruitingFinn, Olivera, PhD502024-02-072026-10-16
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
STX-478, Fulvestrant, Ribociclib - Breast Cancer, Solid Tumors, Adult
Phase 1 / Phase 2RecruitingEli Lilly and Company8802023-04-172026-07-07
Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
EP0062, Elacestrant, Everolimus - Hormone Receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer
Phase 1 / Phase 2RecruitingEllipses Pharma952023-01-112026-06-22
A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors
LOXO-783, Fulvestrant, Imlunestrant - Breast Cancer
Phase 1Active not recruitingEli Lilly and Company2602022-05-112026-10-14
A Study of E7090 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Estrogen Receptor Positive (ER+) and Human Epidermal Growth Receptor 2 Negative (HER2-) Recurrent/Metastatic Breast Cancer
E7090, Fulvestrant, Exemestane - Breast Neoplasms
Phase 1CompletedEisai Co., Ltd.512020-10-092026-07-17
T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer
Anastrozole, Exemestane, Fulvestrant - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8
Phase 1CompletedUniversity of California, San Francisco202020-02-052025-05-21
A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody, Bevacizumab, Entinostat - Breast Neoplasms
Phase 1 / Phase 2CompletedHoffmann-La Roche1442017-12-222025-11-10
Pembrolizumab and Exemestane/ Leuprolide in Premenopausal HR+/ HER2- Locally Advanced or Metastatic Breast Cancer
Pembrolizumab/ Exemestane/ Leuprolide - Premenopausal Breast Cancer
Phase 1 / Phase 2TerminatedNational Taiwan University Hospital162017-09-152023-02-22
GS-5829 in Combination With Fulvestrant or Exemestane in Women With Advanced Estrogen Receptor Positive, HER2 Negative-Breast Cancer
GS-5829, Exemestane, Fulvestrant - Advanced Estrogen Receptor Positive HER2- Breast Cancer
Phase 1 / Phase 2TerminatedGilead Sciences142017-01-102019-08-07
Entinostat in Chinese Postmenopausal Women Patients With Locally Recurrent or Metastatic Breast Cancer
Entinostat, Exemestane - Breast Cancer
Phase 1CompletedTaizhou EOC Pharma Co., Ltd.192016-08-292019-05-07
Palbociclib With Everolimus + Exemestane In BC
Palbociclib, Everolimus, Exemestane - Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Hormone Receptor (HR)-Positive Breast Cancer
Phase 1 / Phase 2CompletedDana-Farber Cancer Institute412016-08-242022-08-29
Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With ER+ Breast Cancer
entinostat, exemestane - Breast Cancer, Estrogen Receptor Positive Breast Cancer
Phase 1CompletedSyndax Pharmaceuticals612016-06-292021-12-15
Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor.
Ribociclib, Everolimus, Exemestane - Breast Cancer
Phase 1 / Phase 2CompletedNovartis Pharmaceuticals1042016-06-142021-05-05
Study of KHK2375 in Subjects With Advanced or Recurrent Breast Cancer
KHK2375, Exemestane - Breast Cancer
Phase 1CompletedKyowa Kirin Co., Ltd.152015-11-012022-06-21
Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alobresib (Formerly GS-5829) in Adults With Advanced Solid Tumors and Lymphomas and in Combination With Exemestane or Fulvestrant in Adults With Estrogen Receptor Positive Breast Cancer
Alobresib, Exemestane, Fulvestrant - Solid Tumors and Lymphomas
Phase 1CompletedGilead Sciences332015-03-162020-12-29
BI 836845 in Estrogen Receptor Positive Metastatic Breast Cancer
Everolimus, Exemestane, BI 836845 - Neoplasms
Phase 1CompletedBoehringer Ingelheim1642014-05-152025-07-15

Showing 20 of 37. Sign in to see all of them.

Conditions studied

Breast Neoplasms (26)  ·  Neoplasms (5)  ·  Breast Diseases (3)  ·  Neoplasm Metastasis (3)  ·  Carcinoma, Non-Small-Cell Lung (2)  ·  Carcinoma, Renal Cell (2)  ·  Neoplasms by Site (2)  ·  Acrocephalosyndactylia (1)  ·  Breast Neoplasms, Male (1)  ·  Bronchial Neoplasms (1)  ·  Carcinoma, Bronchogenic (1)  ·  Carcinoma, Hepatocellular (1)  ·  Carcinoma, Intraductal, Noninfiltrating (1)  ·  Endometrial Neoplasms (1)  ·  Head and Neck Neoplasms (1)

Sponsors

Eli Lilly and Company (3)  ·  Novartis Pharmaceuticals (3)  ·  Boehringer Ingelheim (2)  ·  Gilead Sciences (2)  ·  Pfizer (2)  ·  Syndax Pharmaceuticals (2)  ·  Actavis Inc. (1)  ·  AstraZeneca (1)  ·  Baylor Breast Care Center (1)  ·  Dana-Farber Cancer Institute (1)  ·  Eisai Co., Ltd. (1)  ·  Ellipses Pharma (1)  ·  Finn, Olivera, PhD (1)  ·  Georgetown University (1)  ·  Hoffmann-La Roche (1)

Countries

United States (25)  ·  Spain (7)  ·  Belgium (6)  ·  France (6)  ·  United Kingdom (5)  ·  Germany (4)  ·  Italy (4)  ·  Japan (4)  ·  China (3)  ·  Netherlands (3)  ·  South Korea (3)  ·  Australia (2)  ·  Canada (2)  ·  Hong Kong (2)  ·  Hungary (2)

Top investigators

Amy J Chien, MD (1)  ·  Bruce Pier, MD (1)  ·  Claudine Isaacs, MD (1)  ·  Donal Landers (1)  ·  Edward Garon (1)  ·  Emilia Diego, MD (1)  ·  Francisco J. Esteva, MD, PhD (1)  ·  Howard A Burris, M.D. (1)  ·  Julie Means-Powell, MD (1)

Results publications

PMID 24919854, PMID 31322702, PMID 32864625, PMID 33451345, PMID 34196874, PMID 34819039, PMID 35223458, PMID 39384801, PMID 39730000, PMID 40974664, PMID 41271741

NIH funding

2016 (2), 2017 (1), 2023 (1), N01CM00100 (1), P30CA076292 (1)